Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Venlafaxine Equals Paroxetine for Obsessive-Compulsive Disorder: Presented at APA

        By Bruce Sylvester

        PHILADELPHIA, PA -- May 21, 2002 -- Effexor (venlafaxine) appears to be equally effective to Paxil (paroxetine) for the treatment of obsessive-compulsive disorder (OCD), researchers report.

        The results from the first randomized, double-blind, head-to-head study comparing the two drugs for the treatment of OCD were presented here on May 20 at the annual meeting of the American Psychiatric Association (APA).

        "We wanted to find out how a compound acting on two different brain systems -- serotonin and norepinephrine -- compared in OCD treatment to a compound acting only on serotonin" said lead researcher Harold Van Megen, MD, associate professor of medicine, University of Utrecht, Netherlands. "We found the efficacy of each drug to be comparable."

        Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) and paroxetine is a selective serotonin reuptake inhibitor (SSRI).

        The researchers recruited 150 subjects with primary OCD, according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. In the 12-week trial, they randomly assigned 74 subjects to receive dosages titrated upward to 300 mg/day of venlafaxine and 76 to receive 60 mg/day of paroxetine.

        Efficacy of treatment was assessed according to changes from baseline on the Yale-Brown obsessive-compulsive scale (Y-BOCS). They defined a clinical response as a decrease of 25 percent on the Y-BOCS. They also made assessments with the Hamilton depression rating scale and Hamilton anxiety rating scale.

        The researchers found a 60 percent positive response in both groups of subjects. There was a mean decrease on the Y-BOCS of 30±29.5 percent in the venlafaxine group and of 30±26 percent in the paroxetine group.

        "The take-home message here is about an alternative for patients experiencing difficult side effects on paroxetine," Dr. Van Megan said. "If an OCD patient has side effect problems with paroxetine, we can now say that a switch to venlafaxine could be equally efficacious for OCD treatment."



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send